Otonomy Inc (OTIC) : Ft Options scooped up 36,348 additional shares in Otonomy Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 192,785 shares of Otonomy Inc which is valued at $3,159,746.Otonomy Inc makes up approximately 3.83% of Ft Options’s portfolio.
Other Hedge Funds, Including , Marshall Wace Llp sold out all of its stake in OTIC during the most recent quarter. The investment firm sold 280,927 shares of OTIC which is valued $4,604,394.Credit Suisse Ag boosted its stake in OTIC in the latest quarter, The investment management firm added 7,259 additional shares and now holds a total of 24,528 shares of Otonomy Inc which is valued at $402,014. Raymond James Associates added OTIC to its portfolio by purchasing 63,752 company shares during the most recent quarter which is valued at $1,044,895.Advisors Asset Management reduced its stake in OTIC by selling 30,767 shares or 26.36% in the most recent quarter. The Hedge Fund company now holds 85,932 shares of OTIC which is valued at $1,375,771. Otonomy Inc makes up approx 0.02% of Advisors Asset Management’s portfolio. Rothschild Asset Management Inc added OTIC to its portfolio by purchasing 15,666 company shares during the most recent quarter which is valued at $230,134.
Otonomy Inc opened for trading at $16.07 and hit $16.32 on the upside on Monday, eventually ending the session at $16.19, with a gain of 1.12% or 0.18 points. The heightened volatility saw the trading volume jump to 84,587 shares. Company has a market cap of $488 M.
Many Wall Street Analysts have commented on Otonomy Inc. WallachBeth Initiated Otonomy Inc on May 26, 2016 to “Buy”, Price Target of the shares are set at $29.
Otonomy Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear. The Company’s product candidates include AuriPro OTO-104 and OTO-311. The Company’s lead product candidate AuriPro is a sustained-exposure antibiotic. AuriPro has completed two identical Phase III clinical trials in 532 pediatric patients with middle ear effusion (fluid) at the time of tympanostomy tube placement (TTP) surgery. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. OTO-104 is in a Phase IIb clinical trial at more than 50 centers in the United States and Canada. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. OTO-311 is in preclinical development.